Jefferies, TD Cowen, Stifel and Guggenheim acted as joint book running managers for the offering.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APGE:
- Apogee Therapeutics price target raised to $118 from $108 at Deutsche Bank
- Apogee Therapeutics price target raised to $160 from $130 at Guggenheim
- Apogee Therapeutics price target raised to $125 from $95 at Citi
- Apogee Therapeutics price target raised to $130 from $89 at Canaccord
- Apogee Therapeutics: Strong Phase IIa IL‑13 Data Support Buy Rating and Long-Term Upside in Atopic Dermatitis